New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2014
08:59 EDTBNNY, REGN, RAX, CADX, CVS, DF, GOOG, GRPN, S, GWR, BLOX, SCOR, MNK, XOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Sprint (S), up 7%... Regeneron (REGN), up 3%... CVS Caremark (CVS), up 2%. ALSO HIGHER: Cadence (CADX), up 26.5% after Mallinckrodt (MNK) agrees to acquire the company for about $1.3B, or $14 per share in cash. Mallinckrodt shares also up 9% after the deal... comScore (SCOR), up 15% after earning, partnership deal with Google (GOOG) for real-time audience metric. DOWN AFTER EARNINGS: Infoblox (BLOX), down 42%... Dean Foods (DF), down 11%... Annie's (BNNY), down 9%... Genesee & Wyoming (GWR), down 4%. ALSO LOWER: Rackspace (RAX), down 12% after earnings report, retirement of CEO... Groupon (GRPN), down 5% after SVP product management Jeffrey Holden leaving company... U.S. Steel (X), down 1.8% following downgrade at Citigroup.
News For S;CADX;MNK;GRPN;RAX;SCOR;GOOG;REGN;BLOX;DF;BNNY;GWR;CVS;X From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
March 18, 2015
05:43 EDTGOOGGoogle introduces new app approval process
Subscribe for More Information
March 17, 2015
14:13 EDTGOOGMorgan Stanley questions GM capital allocation plan
Subscribe for More Information
10:45 EDTXStocks with call strike movement; X BBRY
U.S. Steel (X) March 24 call option implied volatility increased 8% to 52, BlackBerry (BBRY) September 11 call option implied volatility decreased 2% to 50 according to IVolatility.
09:27 EDTGOOGApple plans to allow trade-ins of Android, BlackBerry devices, Bloomberg says
Subscribe for More Information
09:07 EDTGOOGDISH's Sling TV launches on Xbox One
Subscribe for More Information
09:05 EDTGOOGMicrosoft Band now available at Best Buy, Target, Amazon, Re/code reports
Subscribe for More Information
07:42 EDTGOOGBoeing may produce satellite for tech giants, Reuters says
Subscribe for More Information
06:50 EDTRAXRackspace volatility at low end of historic range
Subscribe for More Information
06:37 EDTGOOGAfter losing marketshare, Google now asks Firefox users to switch, BI says
Subscribe for More Information
06:31 EDTCVSStudies find Gilead's hepatitis C drugs cost effective, Reuters says
Subscribe for More Information
05:57 EDTGOOGChina vendors to ship 50M Androids with fingerprint sensors, DigiTimes reports
China vendors is expected to ship 50M Android (GOOG) smartphones with fingerprint sensors in 2015, reports DigiTimes. According to sources at Taiwan-based IC backend service companies, Android smartphone vendors have adopted sliding-type fingerprint sensors, which are more competitive in pricing compared to press-type sensors used by Apple (AAPL). Reference Link
March 16, 2015
14:13 EDTGOOGApple to offer Android users rebates to switch to iPhones, 9to5Mac says
Subscribe for More Information
12:42 EDTXU.S. Steel trades lower with peers, levels to watch
Subscribe for More Information
12:39 EDTXSteels stocks lower after report of rising China exports, analyst note
Steel stocks are lower after a Wall Street Journal report on increasing Chinese steel exports and an analyst note that lowered price targets on the sector. WHAT'S NEW: A Wall Street Journal report from Sunday night pointed out that China's steel exports rose 63% to 9.2M tons in January from a year earlier. China produces as much steel as the rest of the world combined and as the country's growth slows it is shipping its excess steel overseas, resulting in lower prices and spurring steel producers around the globe to seek government protection. ANALYST VIEW: In a note to investors, Jefferies said steel fundamentals stayed challenging throughout the first quarter and the firm lowered its price targets on a number of names in the sector to account for its reduced estimates. Jefferies lowered its price target on U.S. Steel (X) to $21 from $26, cut its price target on Schnitzer Steel (SCHN) to $17 from $20, reduced its price target on Nucor (NUE) to $57 from $61, and trimmed its target on AK Steel (AKS) to $3.75 from $4.75. Jefferies noted that a majority of its contacts expect steel prices to trough sometime in the second quarter and the firm said it believes "mini-mill" producers like Steel Dynamics (STLD) and Nucor are best positioned in the group. PRICE ACTION:In midday trading, United States Steel is down 1.24%, AK Steel is lower by 2%, Schnitzer Steel Industries is down 4.3%, Steel Dynamics is down 0.96%, and Nucor is up fractionally.
11:49 EDTXChina steel exports set to rise from last year's level, WSJ says
As China's economy slows it is exporting its excess steel in greater amounts and is causing a backlash from other steel producers who are seeking government protection from falling prices, says the Wall Street Journal. China's steel exports in January were up 63% to 9.2M tons from a year earlier, added the Wall Street Journal. Publicly traded companies in the space include U.S. Steel (X), AK Steel (AKS), Steel Dynamics (STLD) and Nucor Corporation (NUE). Reference Link
08:23 EDTREGNPCSK9 data continues to impress, says Leerink
Subscribe for More Information
08:11 EDTXSteel seen as likely to bottom in Q2 after weak Q1, says Jefferies
Jefferies said steel fundamentals stayed challenging throughout Q1 and the firm lowered its price targets on a number of names in the sector to account for its reduced estimates. Jefferies lowered its price target on U.S. Steel to $21 from $26, cut its price target on Schnitzer Steel (SCHN) to $17 from $20, reduced its price target on Nucor (NUE) to $57 from $61 and trimmed its target on AK Steel to $3.75 from $4.75. Jefferies noted that a majority of it contacts expect steel prices to trough sometime in Q2 and the firm said it believes "mini-mill" producers like Steel Dynamics (STLD) and Nucor are best positioned in the group.
07:16 EDTREGNRegeneron Sanofi dupilumab drug can generate $6B+ in revenue, says Bernstein
Bernstein believes that dupilumab, a drug made by Regeneron and Sanofi, has shown strong efficacy in patients with severe atopic dermatitis. The firm notes that the drug is currently in pivotal trials involving patients with severe levels of other common diseases. The firm thinks the drug can generate $1.5B of revenue by 2018 and $3.8B by 2020. Bernstein keeps a $500 price target and Outperform rating on Regeneron.
06:40 EDTREGNPCSK9 studies show potential improvement in heart health, WSJ says
Subscribe for More Information
March 15, 2015
13:04 EDTREGNSanofi, Regeneron announce publication of results of ODYSSEY long term trial
Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) today announced that 18-month results of a Phase 3 trial of Praluent, alirocumab, an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published online in The New England Journal of Medicine. In the ODYSSEY LONG TERM trial, Praluent 150 mg every two weeks reduced low-density lipoprotein cholesterol by an additional 62% at week 24 when compared to placebo, the primary efficacy endpoint of the study, with consistent LDL-C lowering maintained over 78 weeks."These results demonstrated the durable efficacy for Praluent when added to maximally-tolerated statin therapy and further reinforce its generally consistent safety profile," said Jennifer Robinson, M.D., M.P.H., Director of the Prevention Intervention Center, Professor, Departments of Epidemiology & Medicine, College of Public Health at the University of Iowa. "Additionally, the post hoc analysis of major cardiovascular events represents an important finding for Praluent -- we look forward to results from the ongoing ODYSSEY OUTCOMES trial, which is prospectively evaluating the potential of Praluent to reduce cardiovascular events."
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use